WEBGleostine is an alkylating drug indicated. for the treatment of patients with: and/or radiotherapeutic procedures. disease progression with initial chemotherapy. NextSource Cares® provide Gleostine® (lomustine) …
WEBINTRODUCTION. Drug-induced neutropenia is a potentially serious and life-threatening adverse event that may occur secondary to therapy with a variety of agents. Cytotoxic … Author: Donald C Moore DOI: CrossRef Publish Year: 2016 Publication: P T. 2016 Dec; 41(12): 765-768.
WEBGleostine (lomustine) is an alkylating drug for oral administration. The chemical name for lomustine is 1-(2 chloro-ethyl)-3-cyclohexyl-1-nitrosourea and the molecular formula is … File Size: 178KB Page Count: 10
WEBLOMUSTINE (loe MUS teen) treats brain cancer and lymphoma. It works by slowing down the growth of cancer cells. This medicine may be used for other purposes; ask your …
WEBLomustine is a highly lipid-soluble nitrosourea compound.2 Unlike carmustine, it is administered orally. Lomustine, a monofunctional alkylating agent, alkylates DNA and …
WEBLomustine is administered orally in six-to-eight-week intervals and with nadirs at five weeks after administration due to its delayed myelosuppressive properties. History FDA …
WEBFeb 9, 2020 · Do not administer lomustine more frequently than once every 6 weeks. Dose adjustments should be based on nadir counts from prior dose. The Canadian labeling …
